Jens-Ulrich Rahfeld

Title: Jens-Ulrich Rahfeld: Innovator in Antibody Research

Introduction

Jens-Ulrich Rahfeld is a prominent inventor based in Munich, Germany. He is known for his significant contributions to the field of antibody research, particularly in relation to diseases associated with amyloid peptides. His innovative work has the potential to impact the treatment and diagnosis of various amyloidosis-related conditions.

Latest Patents

Jens-Ulrich Rahfeld holds 1 patent for his invention titled "Humanized and de-immunized antibodies." This invention focuses on antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Aβ N3pE) peptide. The patent addresses preventive and therapeutic treatments for diseases related to the accumulation and deposition of amyloid peptides, such as Alzheimer's disease and Down's syndrome. The invention also includes diagnostic assays for the diagnosis of amyloidosis using these antibodies.

Career Highlights

Throughout his career, Jens-Ulrich Rahfeld has worked with notable companies in the biotechnology sector. He has been associated with Vivoryon Therapeutics N.V. and Probiodrug AG, where he has contributed to advancements in therapeutic solutions targeting amyloid-related disorders.

Collaborations

(Section skipped due to space constraints.)

Conclusion

Jens-Ulrich Rahfeld's innovative work in antibody research exemplifies the potential for scientific advancements to address critical health challenges. His contributions are paving the way for new therapeutic and diagnostic approaches in the fight against amyloidosis and related diseases.